Editorial: Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer
<p dir="ltr">Immune checkpoint blockade (ICB) has been approved as first- or second-line therapy options in a broadening range of metastatic cancer and is increasingly explored in the treatment of early stage tumors. However, clinical responses are limited to a small group of patient...
محفوظ في:
| المؤلف الرئيسي: | Said Dermime (79420) (author) |
|---|---|
| مؤلفون آخرون: | Maysaloun Merhi (4246147) (author), Taha Merghoub (217303) (author) |
| منشور في: |
2021
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
مواد مشابهة
-
Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer
حسب: Said Dermime (79420)
منشور في: (2021) -
Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects
حسب: Remy Thomas (702843)
منشور في: (2021) -
Immune checkpoint inhibitors: recent progress and potential biomarkers
حسب: Pramod Darvin (153341)
منشور في: (2018) -
A community challenge to predict clinical outcomes after immune checkpoint blockade in non-small cell lung cancer
حسب: Mike Mason (18007491)
منشور في: (2024) -
Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4+ T Cells
حسب: Reem Saleh (3513056)
منشور في: (2019)